IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced that an abstract with data from the company's single-arm, Phase 1/2 trial of ... prnewswire.com prnewswire.com / feeds prnewswire-com-financial-services .. prnewswire-com-news-releases / / #money / / 1 day 1d Share
